This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.

The invention concerns a composition and method for treating an ungual infection, the composition comprising an iodophor and dimethylsulfoxide (DMSO).

Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease.

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.

Described herein are compositions composed of peptide nucleic acid strands. In some aspects the peptide nucleic acid strands are complementary to at least a portion of another peptide nucleic acid strand that may have one or more gamma substituents, where the ratio of PNA strands is least 1:1. Certain gamma substituents are capable of effecting attachment of a PNA strand to a cell. The disclosure also concerns construction of nanostructure platforms and vaccines and use of the inventive compositions in inhibiting disease states in mammals.

Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.

An upconversion nanoparticle (UCN) coated with a layer of semiconductor material is disclosed. The UCN core acts as a nanotransducer to convert near infrared (NIR) to visible and/or ultraviolet (UV) light while the semiconductor shell serves as a photocatalyst. Upon excitation by NIR light, the UCN upconverts NIR light to UV and/or visible light of different wavelengths. Spectral overlap between the emitted UV and absorption wavelength of the coated TiO.sub.2 activates the TiO.sub.2 layer to generate cytotoxic reactive oxygen species (ROS), which can be used in photodynamic therapy for the treatment of cancer cells. Stability and uptake of the nanoparticles can be increased by altering the coating of the nanoparticle, such as by a polymer and a dispersion stabilizer.

Nanoparticles that include a chemotherapeutic agent and an anti-inflammatory are particularly cytotoxic to prostate cancer cells.

Ligand-cytotoxic drug conjugates, pharmaceutical compositions, preparation methods, and pharmaceutical uses thereof are provided. More specifically, a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D).sub.n is provided. The ligand-cytotoxic drug conjugate can be used to treat cancer via receptor modulation.

The invention provides anti-CD33 antibodies and immunoconjugates and methods of using the same.